ABT:NYE-Abbott Laboratories (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 111.31

Change

+1.16 (+1.05)%

Market Cap

USD 56.45B

Volume

9.77M

Analyst Target

USD 115.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-02 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
MDT Medtronic PLC

N/A

USD 113.61B
STE STERIS plc

N/A

USD 23.65B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 21.34B
SNN Smith & Nephew SNATS Inc

N/A

USD 13.45B
GMED Globus Medical

N/A

USD 9.84B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.18B
BIO Bio-Rad Laboratories Inc

N/A

USD 9.18B
PEN Penumbra Inc

N/A

USD 7.86B
GKOS Glaukos Corp

N/A

USD 7.36B
INSP Inspire Medical Systems Inc

N/A

USD 5.88B

ETFs Containing ABT

UMDV:SW iShares US Medical Device.. 16.05 % 0.00 %

N/A

N/A
EDOC:AU BetaShares Digital Health.. 8.51 % 0.00 %

N/A

N/A
HART IQ Healthy Hearts ETF 5.20 % 0.00 %

N/A

USD 9.00M
LIFE:CA Evolve Global Healthcare .. 5.05 % 0.69 %

N/A

CAD 0.22B
LIFE-U:CA Evolve Global Healthcare .. 5.05 % 0.00 %

N/A

N/A
HHL-U:CA Harvest Healthcare Leader.. 5.01 % 0.00 %

N/A

N/A
HHL-B:CA Harvest Healthcare Leader.. 5.01 % 0.00 %

N/A

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.68 % 0.00 %

N/A

N/A
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.50 % 0.00 %

N/A

USD 0.15B
XGES:LSE Xtrackers MSCI Genomic He.. 4.35 % 0.00 %

N/A

N/A
PWV Invesco Dynamic Large Cap.. 3.51 % 0.55 %

N/A

USD 1.00B
WELG:XETRA Amundi S&P Global Health .. 3.46 % 0.00 %

N/A

N/A
WELS:XETRA Amundi S&P Global Health .. 3.46 % 0.00 %

N/A

N/A
IUHC:LSE iShares S&P 500 USD Healt.. 3.44 % 0.00 %

N/A

USD 2.48B
QLTY The 2023 ETF Series Trust.. 3.42 % 0.00 %

N/A

USD 0.44B
XLV Health Care Select Sector.. 3.40 % 0.13 %

N/A

USD 42.49B
IUHC:SW iShares S&P 500 Health Ca.. 3.36 % 0.00 %

N/A

N/A
GXLV:LSE SPDR® S&P® U.S. Health .. 3.36 % 0.00 %

N/A

N/A
SXLV:SW SPDR S&P U.S. Health Care.. 3.34 % 0.00 %

N/A

N/A
XUHC:SW Xtrackers MSCI USA Health.. 3.22 % 0.00 %

N/A

USD 0.65B
AIVL WisdomTree Trust - Wisdom.. 2.95 % 0.00 %

N/A

USD 0.40B
HEAL:CA 2.82 % 0.00 %

N/A

N/A
ANEW ProShares MSCI Transforma.. 2.19 % 0.00 %

N/A

USD 8.77M
CURE Direxion Daily Healthcare.. 1.98 % 1.06 %

N/A

USD 0.21B
HYLG Global X Funds - Global X.. 1.58 % 0.00 %

N/A

N/A
FHLC Fidelity® MSCI Health Ca.. 0.00 % 0.08 %

N/A

USD 3.19B
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

N/A

N/A
JHMH 0.00 % 0.46 %

N/A

N/A
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

N/A
QDYN 0.00 % 0.37 %

N/A

N/A
ACT Enact Holdings Inc 0.00 % 0.75 %

N/A

USD 5.56B
RWDC 0.00 % 0.00 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

N/A
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

N/A

N/A
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

N/A

N/A
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

N/A

CAD 0.67B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

N/A
XGDD:LSE Xtrackers - Stoxx Global .. 0.00 % 0.00 %

N/A

N/A
XGSD:LSE Xtrackers Stoxx Global Se.. 0.00 % 0.00 %

N/A

N/A
XSHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.00 %

N/A

USD 0.66B
XUHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.00 %

N/A

USD 0.66B
XSSX:LSE Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

N/A

USD 0.05B
DXSB:F Xtrackers - Stoxx Global .. 0.00 % 0.00 %

N/A

N/A
QDVG:F iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
XUHC:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

N/A

USD 0.85B
ZPDH:F SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

USD 0.40B
DXSB:XETRA Xtrackers - Stoxx Global .. 0.00 % 0.00 %

N/A

USD 0.68B
DXSP:XETRA Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

N/A

USD 0.05B
QDVG:XETRA iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

USD 2.05B
XUHC:XETRA Xtrackers MSCI USA Health.. 0.00 % 0.00 %

N/A

USD 0.85B
ZPDH:XETRA SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

N/A

USD 0.40B
HIG-U:CA 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
IXJ:AU iShares Global Healthcare.. 0.00 % 0.00 %

N/A

USD 1.47B
FUD-A:CA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.13% 52% F 41% F
Dividend Return 1.50% 71% C- 39% F
Total Return 2.63% 55% F 35% F
Trailing 12 Months  
Capital Gain 3.40% 63% D 43% F
Dividend Return 2.01% 71% C- 31% F
Total Return 5.41% 63% D 37% F
Trailing 5 Years  
Capital Gain 29.70% 64% D 64% D
Dividend Return 10.64% 88% B+ 39% F
Total Return 40.34% 72% C 62% D
Average Annual (5 Year Horizon)  
Capital Gain 6.48% 53% F 61% D-
Dividend Return 8.19% 53% F 59% D-
Total Return 1.71% 75% C 39% F
Risk Return Profile  
Volatility (Standard Deviation) 19.09% 84% B 54% F
Risk Adjusted Return 42.88% 78% C+ 62% D
Market Capitalization 56.45B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.70 68% 20%
Price/Book Ratio 4.87 32% 18%
Price / Cash Flow Ratio 26.67 24% 11%
Price/Free Cash Flow Ratio 19.22 17% 16%
Management Effectiveness  
Return on Equity 14.44% 100% 74%
Return on Invested Capital 10.37% 93% 69%
Return on Assets 6.26% 97% 83%
Debt to Equity Ratio 35.23% 63% 69%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector